Esther Lee, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1518176007
Payments from drug & device makers
Across 96 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$362
- Insulet Corporation$217
- BETA Bionics, Inc.$207
- Dexcom, Inc.$128
- Corcept Therapeutics$118
- Lilly USA, LLC$109
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,31898%
- Education$432%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 21 | $362 |
| Insulet Corporation | 3 | $217 |
| BETA Bionics, Inc. | 4 | $207 |
| Dexcom, Inc. | 2 | $128 |
| Corcept Therapeutics | 5 | $118 |
| Lilly USA, LLC | 6 | $109 |
| Regeneron Healthcare Solutions, Inc. | 5 | $105 |
| Actelion Pharmaceuticals US, Inc. | 4 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $101 |
| Medtronic | 1 | $91 |
| UCB, Inc. | 4 | $76 |
| Novo Nordisk | 5 | $76 |
| Mannkind Corporation | 3 | $75 |
| Johnson & Johnson | 3 | $63 |
| Abbott | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Bayer | 2 | $43 |
| Inspire Medical Systems, Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 2 | $39 |
| Boehringer Ingelheim | 2 | $36 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| Grifols USA, LLC | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $25 |
| Amgen | 1 | $23 |
| Pfizer | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $20 |
| Electromed, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $16 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$422
- Omnipod$107
- DEXCOM G6 TRANSMITTER$100
How this compares
$2,361 in reported general payments places this provider in the 40th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 196 | $315,738 |
| MounjaroTirzepatide | 74 | $110,912 |
| TrulicityDulaglutide | 71 | $109,918 |
| JardianceEmpagliflozin | 71 | $95,103 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $94,331 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $60,025 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $28,341 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $28,338 |
| Humalog Kwikpen U-100Insulin Lispro | 58 | $24,845 |
| FarxigaDapagliflozin Propanediol | 34 | $22,985 |
| RybelsusSemaglutide | 15 | $19,855 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $18,778 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 11 | $18,410 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $13,502 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 35 | $13,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $76 | $335,592211 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $109 | $231,159175 claims |
| Boehringer IngelheimJardiance | $36 | $95,10371 claims |
| AstraZenecaFarxiga | $362 | $22,98534 claims |
| AbbVieSynthroid | $14 | $3,81630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- David RobertsonAtlanta$1.7M
- Thomas ZieglerAtlanta$1M
- Lawrence PhillipsAtlanta$919K
- Georgia DavisAtlanta$592K
- Jonathan OwnbyAtlanta$565K
- Thaer IdreesAtlanta$505K
- Francisco PasquelAtlanta$376K
- Mary RheeAtlanta$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.